CRISPR Therapeutics AG (CRSP) Receivables - Net (2015 - 2024)
CRISPR Therapeutics AG (CRSP) posted Receivables - Net of $25.0 million for Q4 2024, down 87.5% sequentially from $200.0 million in Q4 2023, and down 87.5% YoY from $200.0 million in Q1 2024.
CRISPR Therapeutics AG (CRSP) Receivables - Net (2015 - 2024) Analysis & Trends
CRISPR Therapeutics AG has reported Receivables - Net for 10 years, with the latest figure at $25.0 million in Q4 2024.
- Quarterly Receivables - Net fell 87.5% year-over-year to $25.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $25.0 million (down 87.5% YoY) and the FY2024 annual result came in at $25.0 million, down 87.5% from the prior year.
- Receivables - Net slipped to $25.0 million in Q4 2024 per CRSP's latest filing, from $200.0 million in the prior quarter.
- Over five years, Receivables - Net peaked at $200.0 million in Q4 2023 and troughed at $33000.0 in Q2 2020.
- A 5-year average of $23.0 million and a median of $150000.0 in 2021 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2020 and 2023: Receivables - Net tumbled 99.44% in 2020, then soared 105960.61% in 2023.
- Over 5 years, Receivables - Net stood at $144000.0 in 2020, then jumped by 111.81% to $305000.0 in 2021, then plunged by 83.93% to $49000.0 in 2022, then soared by 408063.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024.
- According to Business Quant data, Receivables - Net over the past three periods registered $25.0 million, $200.0 million, and $70.0 million for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Sep 30, 2022 | 49,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Mar 31, 2022 | 143,000.00 |
| Mar 31, 2022 | 143,000.00 |
| Dec 31, 2021 | 305,000.00 |
| Dec 31, 2021 | 305,000.00 |
| Sep 30, 2021 | 152,000.00 |
| Sep 30, 2021 | 152,000.00 |
| Jun 30, 2021 | 150,000.00 |
| Jun 30, 2021 | 150,000.00 |
| Mar 31, 2021 | 150,000.00 |
| Mar 31, 2021 | 150,000.00 |